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CHAPTER 1 
DESIGN AND SYNTHESIS OF ISATIN-BASED CASPASE INHIBITORS FOR 
RUTHENIUM CAGING APPLICATIONS 
1.1 Introduction 
1.1.1 Apoptosis and Caspases 
 Apoptosis is a process of cell degradation in eukaryotes. This process is mediated by 
specific signaling cascades. The ultimate result of apoptosis is programmed cell death. This 
significant cellular process is directly co-related with embryogenesis, the immune system, ageing 
and various diseases including cancers, ischemic vascular diseases and neurodegenerative 
disorders such as Alzheimer’s disease, Parkinson’s disease and Huntington’s disease.1  
 An intracellular proteolytic cascade is involved in regulating apoptosis. This process 
depends on a protease enzyme class called caspases (cysteinyl dependent aspartate directed 
specific proteases). Caspases exist as inactive proenzymes (called zymogens) that are activated 
via proteolytic pathways to form two subunits. A characteristic feature of caspases is the 
presence of cysteine and histidine residues in the active site. These amino acids carry out 
cleavage of the peptide bond next to aspartic acid residues. The reaction mechanism of peptide 
hydrolysis is shown below (Figure 1-1). The cleaved peptide sequence is designated as an amino 
acid chain Pn-P3-P2-P1-P1’-P2’-P3’-Pn’ and its corresponding substrate binding site is designated 
as Sn-S3-S2-S1-S1’-S2’-S3’-Sn’.
2
 Caspases have a unique preference for aspartic acid at P1 that 
binds specifically to the S1 subsite. Caspases specifically cleave the peptide from its C-terminal 
next to this aspartic acid. The catalytic efficiency is drastically reduced if a different amino acid 
is substituted at P1 in the substrate. The cleavage preference for aspartic acid over glutamic acid 
in the S1 subsite is more than 20,000 fold.
3 
It is also reported that the S3 subsite prefers glutamine 
2 
 
 
residue in all mammalian caspases. Therefore, the specific tetrapeptide sequence can be 
identified as X-Glu-X-Asp for mammalian caspases.
2
  
 
 
 
 
 
 
 Caspases are divided into different classes according to their roles in the signaling 
cascades of apoptosis (Table 1-1). Caspases 6, 8, 9 and 10 are initiators and found at the 
beginning of the signaling cascade. Those caspases activate the effector caspases. Caspases 2, 3 
and 7 are executioner/effector caspases which are found downstream in the signaling cascade.
4
 
Caspases 1, 4, 5 and 13 are involved in inflammation and they are not active in the cell death 
process. Caspases 2, 3 and 7 are the most significant and studied caspase types because they are 
involved in almost all apoptotic models.
5
 
 
 
 
Enzyme class Caspase type 
1- Initiators 6, 8, 9, 10 
2- Executioners 2, 3, 7 
3- Inflammation 1, 4, 5, 13 
Table 1-1. Caspase types and classes 
Scheme 1-1: Mechanism of the peptide bond hydrolysis by cysteine thiol 
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1.1.2 Caspase inhibition 
 Extensive research has been conducted on caspases and their pharmacological activity 
because they are important targets in drug discovery.
2-8
 Development of novel caspase inhibitors 
is attractive medicinally and pharmaceutically to prevent diseases caused by dysregulated 
apoptosis. Caspase inhibitors can be categorized as natural and synthetic inhibitors. Natural 
inhibitors are sub-categorized as viral and cellular caspase inhibitors. Synthetic inhibitors are 
based on peptidomimetic and non-peptidyl compounds.
7
  
1.1.2.1 Natural Caspase inhibitors 
 
 Previous studies showed the involvement of viral and cellular caspase inhibitors in 
apoptosis. For example, Cytokine Response modifier A (CrmA), a product of cowpox virus and 
a member of the serpin superfamily of protease inhibitors, has been identified as a Caspase-1 
inhibitor.
 
A baculoviral protein, p35, is an inhibitor for both insect and mammalian caspases.
 
Mammalian caspase inhibitors such as Survivin and XIAP are reported as specific caspase-3 
inhibitors.
7
 
 Various synthetic caspase inhibitors have also been reported.
6-14
 Development of 
synthetic caspase inhibitors is important to gain specificity in caspase inhibition. These inhibitors 
are categorized as either peptide and non-peptide-based compounds. 
1.1.2.2 Peptidomimetic caspase inhibitors  
 Peptidomimetic caspase inhibitors have been developed according to their structural 
properties and interactions with the substrate cleavage sites of caspases. Caspases identify 
specific binding regions of peptide substrates according to the peptide sequence of the substrate. 
Caspases preferentially cleave the peptide bonds next to aspartate residues due to the stability 
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caspases gain from interactions of cysteine and histidine residues in the active binding region. 
Thus, an aspartate is typically included at the P1 position in most peptidic inhibitors. 
 Various caspase inhibitors have been reported which inhibit different caspases.
6
 For 
example Ac-YVAD-CHO is a potent caspase-1 inhibitor which prevents release of interleukin-
1β (IL-1β) from monocytes. Peptide-based caspase inhibitors can be categorized according to the 
number of aspartyl residues present in the peptide and the number of peptide units present in the 
compound.
7
 For example Boc-Asp-fluoromethylketone (Boc-D-FMK) is a broad-range caspase 
inhibitor containing a single aspartyl residue. Z-VAD-FMK is a tri-peptide that competitively 
and irreversibly inhibits caspases 1-10.
7
 Tetrapeptides have also been developed and their 
structures are significant for substrate specificity. The tetrapeptide inhibitors generally have 
higher potency against caspases because they contain a tetrapeptide region which is specifically 
recognized by the enzyme (Table 1-2).
6,7
 
 According to previously reported caspase inhibition data (Table 1-2), the significance of 
peptide aldehyde sequences has been established. For example, Ac-WEHD-CHO 1 specifically 
binds to group I caspases and Ac-DEVD-CHO 2 binds with group II caspases. 
 Peptide aldehydes such as Ac-WEHD-CHO 1, Ac-DEVD-CHO 2, Boc-IETD-CHO 3 and 
Boc-AEVD-CHO 4 are caspase-3 inhibitors (Figure 1-1).
6,7
 The specificity of these inhibitors for 
different caspases has been desired for many years. Halomethyl ketone containing peptide 
derivatives are highly reactive irreversible inhibitors. Thus they lack specificity towards a 
specific caspase. Peptides containing aldehyde, ketone and nitrile groups are reversible inhibitors 
of caspases.
11
 Some peptide-based caspase inhibitors have not shown good efficacy (IC50 < 1 
5 
 
 
µM) in cellular apoptotic models.
6-8
 Lower cell permeability of these peptidyl inhibitors limits 
the efficacy. Thus, use of peptidyl compounds as caspase inhibitors in vitro is limited.  
 
Enzyme Aldehyde Ki (nM) 
 WEHD YVAD DEVD IETD AEVD 
Group I      
Caspase-1 0.056 0.76 18 <6 <12 
Caspase-4 97 362 132 400 375 
Caspase-5 43 163 205 223 438 
Group II      
Caspase-3 1960 >10,000 0.23 195 42 
Caspase-7 >10,000 >10,000 1.6 3280 425 
Caspase-2 >10,000 >10,000 1710 9400 >10,000 
Group III      
Caspase-6 3090 >10,000 31 5.6 52 
Caspase-8 21.1 352 0.92 1.05 1.6 
Caspase-9 508 970 60 108 48 
Caspase-10 330 408 12 27 320 
  
 
 
 
Table 1-2. Inhibition of caspases by peptide aldehydes
6 
Amino acid sequences are shown as Ac-XXXX-CHO (Refer Figure 1-1 for structures) 
 
6 
 
 
 
 
 
 
 
 
 
 
 
 
 Research has been conducted to develop peptidomimetic caspase inhibitors to increase 
their potencies and selectivities against specific caspases. Peptidomimetic caspase-1 inhibitors 
such as IDN-6556 and VX-765 are already being investigated in clinical trials (Figure 1-2).
10
  
 
 
 
 
 Prodrug VX-765 has been used to design nitrile based peptidomimetic caspase inhibitors 
using SAR studies (Figure 1-3).
11
 For example, compounds 6 and 8 have reported IC50 values of 
1 2 
4 3 
>50 µM 1 µM 
0.6 µM >50 µM 
Figure 1-1: Previously reported tetrapeptide-based caspase-3 inhibitors 
Figure 1-2: Caspase-1 inhibitors IDN-6556 and VX-765 
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2.58 nM and 0.023 nM against caspase-1, respectively. Compounds 6 and 8 show different 
potencies against other caspases (Table 1-3). 
 
 
 
 
 
 
 
 
 
 
 Later studies revealed that a greater selectivity and efficacy could be achieved using non-
peptidomimetic compounds as caspase inhibitors.
9-14 
Molecular modeling with computational 
studies has been used to design potent small molecular caspase inhibitors.
14,15
 Structure activity 
Compound Caspase type, nM 
1 3 4 5 6 7 8 9 10 14 
6 2.58 >10000 1380 1300 >10000 >10000 >10000 91.5 >10000 >10000 
8 0.023 >10000 13.8 3.60 >10000 >10000 25.2 2.17 89.7 801 
5 6 
7 8 
Figure 1-3: Nitrile-based Caspase inhibitors 
Table 1-3. IC50 values for 6 and 8 against different caspases
11 
8 
 
 
relationship studies have also been conducted in order to develop highly potent and specific 
caspase inhibitors. Small molecular caspase inhibitors have shown greater specificity towards 
various caspases than peptidomimetic inhibitors. These inhibitors contain various functional 
groups such as isoquinoline, sulfonamide and nitriles.
9,13,14 
1.1.2.3 Caspase-3 inhibitors 
 Caspase-3 is one of the executioner caspases frequently involved in most 
pharmacological models of apoptosis and their signaling cascades. It is known to be activated in 
most of the apoptotic cellular processes.
5
 Therefore caspase-3 is a significant molecular target for 
studying apoptosis and its functions. Selective caspase-3 inhibitors have potential as therapeutic 
agents. Isatin- and isoquinoline-based caspase-3 inhibitors have been reported.
9,13-17
 Some of the 
reported caspase-3 inhibitors have been further investigated in preclinical studies.
10 
1.1.2.4 Modified isatin sulfonamides as non-peptidomimetic caspase-3 inhibitors 
 
 In 2000, SmithKline Beecham conducted a high-throughput screen using their compound 
library in order to identify non-peptidic small molecules that inhibit caspase-3.
14 
Several 5-
nitroisatins were identified (Figure 1-4). Later studies showed that the presence of electron-
withdrawing groups (EWG) such as nitro and cyano groups were necessary for higher potency.
13
 
The higher potency is attributed to the interaction of the active site cysteine thiol with the C-3 
ketone of isatin. The thiol-ketone interaction is enhanced upon increasing the electrophilicity of 
C-3 (Scheme 1-2). Thus, an EWG at C-5 of isatin is required for higher inhibition, which makes 
the C-3 more susceptible for nucleophilic attack. Compounds 9 and 14 contain EWGs such as 
nitro and cyano on C-5 and show higher potency against caspase-3. Compound 13 has a 
9 
 
 
carboxylate group at C-5, which limits the electrophilicity of C-3 and shows lower potency 
(Figure 1-5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Use of 5-N,N-dialkylisatin sulfonamides as potential caspase-3 inhibitors has been 
investigated.
13,14
 The nitro group at C-5 has been substituted with a 5-sulfonamide group to 
Figure 1-4. IC50 values of 5-nitroisatins as caspase-3 inhibitors
14 
9 10 11 
3 µM 1 µM 0.25 µM 
Figure 1-5. IC50 values of previously reported caspase-3 inhibitors
13 
12 9 
14 13 
>50 µM 1 µM 
0.6 µM >50 µM 
Scheme 1-2. Thio hemiketal formation between C-3 ketone and cysteine-163 thiol 
10 
 
 
increase metabolic stability. Different amine substituents have also been used to investigate the 
caspase-3 potency and found that the incorporation of a pyrrolidine moiety is favorable for 
higher potency (Figure 1-6).
13
 The stereochemistry of this pyrrolidine moiety (15 and 17), cyclic 
vs acyclic structures (15 and 19), and ring sizes (16, 18 and 20) have been examined in inhibition 
studies. Incorporation of an S-2-methoxymethyl group in the pyrrolidine ring (15) yields a higher 
potency than its enantiomer, R-2-methoxymethyl (17). The ring size of pyrrolidine does not 
significantly change the potency (16, 18 and 20).  The acyclic analog of the pyrrolidine moiety 
(19) is less potent than its cyclic analog (15).
13 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-6. IC50 values of Pyrrolidinyl-5-sulfoisatin analogs against caspase-3 according to their 
                    structural properties
13 
15 
17 
19 
16 
18 
20 
910 nM 1,900 nM 
18,000 nM 
2,200 nM 
120 nM
 
2,800 nM 
11 
 
 
 Isatin sulfonamides inhibits executioner caspases (caspase-3 and -7).
13
 In 2000, X-ray 
crystallographic data of caspase-3 bound with an isatin analog, 1-methyl-5-(2-phenoxymethyl-
pyrrolidine-1-sulfonyl)-1h-indole-2,3-dione 21 in the active site of the enzyme were reported 
(Figure 1-7).
14 
 Some key interactions between the inhibitor and caspase-3 were identified. 
Formation of a tetrahedral thio hemiketal intermediate was observed between the thiol of 
cysteine-163 and the C-3 ketone of 21. Interaction with His-121 was also observed. Hydrophobic 
interactions occurred between the S2 pocket and the pyrrolidine ring of 21. A hydrophobic 
interaction of Tyr-204 with one face of the isatin core enhances the binding of inhibitor (Figure 
1-7 and Figure 1-8).
14
   
 
 
  
 
 
 
 
 
 
 
Figure 1-8. Enzyme binding pockets and binding site of isatin analog 21 
Figure 1-7. X-ray crystallographic data of 21 bound within active site of caspase-3
14 
Cys-163 
His-121 
Tyr-204 
12 
 
 
 Modifying isatin sulfonamide analogues with pyrrolidine groups has significant effects 
on caspase inhibition.
13
 For example, various pyrrolidinyl-5-sulfoisatins inhibit caspase-3 and -7 
(Figure 1-9). Isatin sulfonamide analogs were modified according to structure activity 
relationships and their potencies in cellular apoptosis assays were determined. The inhibition of 
executioner caspases (caspase-3 and -7) is critical to prevent apoptosis in multiple cell types. 
Human Jurkat T cells and chondrocyte cells have been used to evaluate the cell death process in 
a previous study.
13
 FACS (Fluorescence Activated Cell Sorter) analysis was used to investigate 
camptothecin-induced apoptosis in Jurkat and chondrocyte cells. Compound 15 inhibited 
apoptosis of Jurkat cell by 54% at 50 µM which was in good correlation with in vitro studies.
13
 
 Chondrocyte apoptosis was investigated because of its relevance to osteoarthritis (OA). 
Osteoarthritis is a degenerative joint disease in which erosion of articular cartilage occurs. 
Chondrocytes, the only cell type specific to cartilage tissue, are a good candidate to monitor 
increased levels of apoptosis. A gene, bcl-2 is involved in apoptosis has been highly expressed in 
chondrocytes adjacent to OA lesions. The fibrillar collagen network is degraded upon 
progression of OA. Thus, chondrocyte cell death is increased.
13
 Similar results were obtained for 
compound 15 for inhibition of chrondocyte apoptosis which showed 98% inhibition at 50 µM. 
Recent cell apoptosis studies show that modified isatin sulfonamide analogs inhibit apoptosis in 
human umbilical vein endothelial cells (HUVEC).
17
 Western blot analysis indicates the cleavage 
of a general caspase substrate PARP (poly ADP ribose polymerase), which correlates with 
caspase activity in cellular apoptosis.
13,17
 PARP is a well known DNA repair enzyme and a 
substrate for caspase-3 cleavage in cellular apoptosis.
12
 PARP is cleaved into 29 kDa and 85 kDa 
subunits by caspase-3 during apoptosis and cleavage can be monitored using Western blot 
analysis. This analysis has been extensively used in research to monitor cellular apoptosis.  
13 
 
 
 The 2-phenoxymethyl pyrrolidinyls did not show cellular apoptosis inhibition activity up 
to 300 µM and are less potent than 2-methoxymethyl pyrrolidinyl compounds.
17
 This observation 
implies that phenoxymethyl pyrollidinyls (24) have lower cell penetration properties
17
 than that 
of methoxymethyl pyrollidinyls. The lipophilicity of these compounds is a major factor for their 
cell penetration properties. These properties were taken into account in the designing process of 
pyrollidinyl sulfo isatins as caspase-3 inhibitors.
13-17  
 
 
 
 
 
 
 
 
 
1.1.3 Ruthenium complexes for caging applications 
 Metal complexes are important therapeutics and tools for biological applications.
18-31 
The 
caging of biologically active molecules with metal complexes has been explored recently.
31-35
 
Photocaging is an established method in biological and medicinal research. It enhances our 
ability to investigate living systems by providing spatial and temporal control over the release of 
the biologically active molecules.
31-35
  
Figure 1-9. Previously reported Ki values of pyrrolidinyl-5-sulfoisatin analogs with caspase-3
17 
15 
23 24 
22 
56.1 nM 8.3 nM 
1.2 nM 
41.8 nM
 
14 
 
 
 Ruthenium compounds have been used to develop caged complexes for several reasons. 
Ru-based compounds have unique photochemical properties which allow photoreactions to 
proceed with visible light, which is less harmful towards biological systems than UV light. 
Various biologically active compounds have been caged with Ru-complexes.
31-35
 Those bio-
active compounds contain functional groups that cannot be caged with organic photolabile 
groups. Recently reported bioactive molecules contain nitriles, N-containing heteroaromatics and 
thioethers that strongly bind to the metal center. Recently, neuroactive biomolecules (4-
aminopyridine 25) 
31-33
, bio-active thioethers
34
 (D-biotin 26 and N-acetyl-L-methionine 27) as 
well as small molecular enzyme inhibitors (28)
35
 have been reported to be caged with these Ru-
based complexes (Figure 1-10). A long-term goal of compounds like these is to achieve spatial 
and temporal release over drug release that could be used to treat various diseases. 
  
 
 
 
 
  
 
 Ruthenium polypyridyl compounds are excellent candidates for caging of small 
molecules. Various ruthenium polypyridyl groups have also been developed as efficient caging 
groups. The complexes Ru(bpy)2 (bpy = 2,2’-bipyridne) (29, 30) and Ru(terpy)(bpy) (31) are 
Figure 1-10. Previously reported photocagable biologically active compounds 
25 26 
28 27 
15 
 
 
leading examples.
31-35
 They show attractive photochemical properties, including stability in the 
dark and efficient release upon irradiation with visible light. Importantly, their Ru-caged 
byproducts show low toxicity. These Ru-polypyridyl complexes consist of planar heteroaromatic 
ligands with highly conjugated, extended π-electron systems that enhance their photolabile 
properties (Figure 1-11).  
 
  
 
 
 
 
1.2 Research objectives 
 
 The aim of this study is to develop novel caspase-3 inhibitors which can be caged with 
ruthenium complexes. These light activated Ru complexes can then be used as tools for chemical 
biology and as potential therapeutics. Development of light activated compounds has advantages 
when compared to general small molecules. A unique advantage of light activation is the ability 
to control time, location and concentration of the biologically active compounds in vitro and in 
vivo. Therefore, light activated caspase-3 inhibitors could be used as a chemical tool to block 
apoptotic induction at specific sites in vivo. In the long term, the spatial and temporal control 
could be used to treat various diseases caused by dysregulation of apoptosis.   
Figure 1-11: Chemical structures of caged ruthenium complexes 
30 31 29 
16 
 
 
CHAPTER 2 
2.1 Results 
2.1.1 Designing of Caspase-3 inhibitors 
 The novel caspase-3 inhibitors developed in this study were designed based on several 
factors. Recent studies show that various 5-pyrrolidinylsulfonyl isatins act as caspase-3 
inhibitors. Thus, we decided to design compounds based on a 5-pyrrolidinylsulfonyl isatin core. 
This small molecule inhibitor could be modified accordingly to develop light activated 
ruthenium complexes. Higher caspase-3 inhibition was desired in the designing process. Several 
findings in previous studies were considered when designing high potent caspase-3 
inhibitors.
13,15-17
 Use of specific stereochemistry in the pyrrolidine moiety is important since S-
alkoxypyrrolidine is more potent than its R-stereoisomer against caspase-3. Methoxymethyl 
pyrrolidinyl analogs show higher cell permeability and lower lipophilicity than phenoxymethyl 
pyrrolidines, thus methoxymethyl pyrrolidine analogs were chosen for further studies. When 
designing the ruthenium-caged inhibitors, the chosen analogs should contain a group that has 
caging and photolabile properties. Therefore, pyridyl and cyano groups were introduced into 
these isatin sulfonamide analogs. Therefore 4-methylpyridine and cyanoethyl groups were 
selected to be attached to the N-1 position, resulting in compounds 32 and 33 (Figure 2-1).   
 
 
 
Figure 2-1. Proposed pyrrolidinyl-5-sulfoisatin analogs for caging studies 
33 32 
17 
 
 
2.2 Synthesis of designed isatin sulfonamide analogs 
 The designed analogs were synthesized using literature and modified procedures
13-17, 36-39
 
(Scheme 2-1). Compound 15 was synthesized as the precursor for the final analogs 32 and 33. 
First, isatin was sulfonated at its C-5 position using fuming sulfuric acid containing 20% SO3 to 
obtain 34. Then according to the procedure reported previously,
17
 5-chlorosulfonyl isatin 35 was 
synthesized. The procedure was optimized to increase the yield. The condensation of 35 with 36 
was performed in a 1:1 CHCl3/THF solvent system in the presence of diisopropylethylamine 
(DIPEA). The reaction from 35 to 15 was challenging because 15 has lower solubility in most of 
the solvents thus giving low yields for 15. Compound 15 was purified and isolated using flash 
column chromatography in 45% yield.  
 
 
 
 
 
 
 
 
 
  
 Compounds 32 and 33 were synthesized using modified and optimized procedures 
(Scheme 2-3 and Scheme 2-4). Compound 32 was synthesized using N-alkylation of 15 with 4-
bromomethylpyridine (37). In this reaction compound 37 needed to be used as a free base 
Scheme 2-1. Synthesis route for compound 15 
15 
34 
35 
36 
18 
 
 
(Scheme 2-2) to avoid formation of an undesired side products which could lower yield of 32. 
The synthesis of 33 proceeds through a base-catalyzed addition reaction of 15 with acrylonitrile. 
The reason for the low yield obtained for 33 might be the formation of polymers with 
acrylonitrile, consistent with TLC analysis which showed a complex mixture of products. The 
proposed reaction mechanisms for the formation of 32 and 33 are outlined below (Scheme 2-5 
and Scheme 2-6).  
 
 
 
 
 
 
 
 
 
 
 
 
 Inhibition studies were done on 32 and 33 with human recombinant caspase-3. These 
enzyme inhibition assays were performed by the undergraduate researcher Veronica Lewalski.  
IC50 values were calculated according to the enzyme inhibition data. Compound 32 showed an 
IC50 of 89 nM and 33 showed IC50 of 560 nM.
40 
 
15 33 
Scheme 2-4. Synthesis of analog 33 
15 32 37 
Scheme 2-3. Synthesis of analog 32 
Scheme 2-2. Synthesis of 37 as a free base 
37 
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Scheme 2-6. Mechanism for formation of 33 
Scheme 2-5. Mechanism for formation of 32 
І 
32 15 
37 
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CHAPTER 3 
3.1 Conclusion 
 The novel compounds 32 and 33 were synthesized successfully and their inhibitory 
effects were studied. The compounds 32 and 33 were both potent inhibitors of caspase-3. 
Compound 32 was more potent than compound 33. Thus compound 32 was selected for further 
ruthenium caging studies. 
3.2 Future directions 
 The designed compound 32 is expected to be caged with ruthenium polypyridyl 
complexes. The caged ruthenium complexes will be subjected to light activation experiments 
where the IC50 values of caged complexes under light and dark conditions will be determined 
and compared. Higher stability and lower potency will be desired for caged Ru-complexes in 
dark conditions. A higher dark/light inhibition ratio is desired and expected for 32. Then 
photoinduced cell toxicity studies could be performed with these ruthenium caged complexes to 
monitor caspases-3 inhibition in different cell models. Cellular models of apoptosis such as 
Jurkat cells, chondrocytes, neutrophils from mouse bone marrow and HUVEC cells can be used 
to evaluate cellular toxicities of the designed compounds. 
 The spatial and temporal controlling experiments could be done for the developed Ru-
complexes in various biological systems and animal models and apoptosis in these systems could 
be monitored. The reduction of the cellular apoptosis is desired upon light activation of these Ru-
caged complexes. The cellular death could be monitored using various imaging methods. These 
combined experiments and results could lead to the development of novel tools to treat 
dysregulated apoptosis in biological systems that can be used to prevent various diseases. For 
21 
 
 
example, in vivo experiments could be carried out to study cardiomyocyte apoptosis (in 
myocardial ischemia model) and evaluate the heart muscle and tissue damage in mouse models. 
These designed compounds can also be used to evaluate apoptosis in bacterial meningitis models 
to study neuronal cell degaradation and also in hepatitic models to study liver damage in mouse 
models. These experiments could be carried out to develop efficient therapeutic methods such as 
photodynamic therapy to treat diseases caused by apoptosis. 
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3.3 Experimental 
3.3.1 General considerations 
 All reagents were purchased from commercial suppliers and used as received. NMR 
spectra were recorded on a Varian FT-NMR Mercury-400 Spectrometer. IR spectra were 
recorded on a Bruker Tensor 27 FT-IR spectrophotometer (KBr pellet). High resolution (HRMS) 
electrospray (ESI-TOF) mass spectra were recorded on a Micromass LCT spectrometer. Melting 
points were recorded on Thermo scientific 9100 melting point apparatus. Enzymatic assays were 
performed on a Tecan Infinite F200Pro microplate reader. All reactions were performed under 
ambient atmosphere unless otherwise noted. Anaerobic reactions were performed by purging the 
reaction solutions with Ar or N2. 
3.3.2 (S)-5-((2-(methoxymethyl) pyrrolidin-1-yl)sulfonyl)-1-(pyridin-4-ylmethyl)indoline-
2,3-dione (32) 
 
 
 
 
To a stirred solution of 15 (0.936 g, 2.89 mmol) in DMF (40 mL), 60% NaH in mineral oil 
(0.174 g, 7.23 mmol) was added at 0 °C. The reaction was stirred for 30 min under Ar 
atmosphere. Then a solution of 4-bromomethyl pyridine 37 was prepared as follows. 4-
bromomethyl pyridine hydrobromide salt (0.873 g, 3.46 mmol) was dissolved in DMF (15 mL) 
and Na2CO3 (0.367 g, 3.46 mmol) was added and stirred for 10 min. The filtrate of 37 was added 
dropwise to the reaction mixture over 10 min and stirred for additional 4 h at 0 °C under Ar 
32 
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atmosphere. The reaction was diluted with EtOAc (60 mL) and washed with saturated aqueous 
NaCl (3 × 40 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated in 
vacuo. The crude product was purified by silica gel chromatography using 1% MeOH:CH2Cl2 
solvent system. The isolated fractions containing product were combined and concentrated in 
vacuo and further crystallized using EtOAc:hexanes. The product was isolated as a bright yellow 
solid. Yield: 0.730 g (1.76 mmol, 61%). mp = 172-174 °C. 
1H NMR (400 MHz, DMSO): δ 8.51 
(d, 2H, J = 4.4 Hz), 8.01 (d, 1H, J = 8.4 Hz), 7.84 (s, 1H), 7.46 (d, 2H, J = 4.4 Hz), 7.08 (d, 1H, J 
= 8.0 Hz), 4.99 (s, 2H), 3.67 (m, 1H), 3.41 (dd, 1H, J = 9.6 Hz, 3.6 Hz), 3.32 (s, 3H), 3.26 (t, 
2H), 3.06 (m, 1H), 1.73 (m, 2H), 1.48 (m, 2H). 
13
C NMR (100 MHz, DMSO): δ 181.7, 159.2, 
153.3, 150.2, 144.8, 136.9, 132.3, 123.1, 122.6, 118.9, 111.8, 74.9, 59.1, 58.9, 49.4, 42.7, 28.7, 
24.0. IR (νmax) (KBr): 3443, 2929, 2361, 2342, 1747, 1616, 1478, 1450, 1417, 1365, 1344, 1330, 
1199, 1181, 1154, 1130, 1115, 1070, 1041, 994. HRMS (ESI-TOF): calc’d for C21H25N3O6NaS 
(M+MeOH+Na)
+
 470.1362, found: 470.1339.  
3.3.3 (S)-3-(5-((2-(methoxymethyl) pyrrolidin-1-yl)sulfonyl)-2,3-dioxoindolin-1 
yl)propanenitrile (33) 
 
 
 
 
To a stirred solution of 15 (0.200 g, 0.620 mmol) in DMF (10 mL), KOH (0.004 g, 0.062 mmol) 
was added and stirred for 10 min at RT. Then acrylonitrile (45 µL, 0.68 mmol) was added 
dropwise and stirred for 2 days at RT under Ar atmosphere. The reaction mixture was added to 
H2O (30 mL), and extracted with EtOAc (3 × 20 mL). The combined organic layer was washed 
33 
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with 10% aqueous NaCl (3 × 20 mL). The organic layer was dried over anhydrous Na2SO4 and 
concentrated in vacuo. The crude product was purified by silica gel chromatography with 1% 
MeOH:CH2Cl2 to afford a yellowish-orange solid. Yield: 0.064 g (0.169 mmol, 27%). mp = 134-
138 °C. 
1
H NMR (400 MHz, CDCl3): δ 8.15 (d, 1H, J = 2 Hz, 8.4 Hz), 8.11 (d, 1H, J = 2 Hz), 
7.19 (d, 1H, J = 8.0 Hz), 4.10 (t, 2H), 3.77 (m, 1H), 3.57 (dd, 1H, J = 4.0 Hz, 9.2 Hz), 3.43 (m, 
1H), 3.38 (d, 1H, J = 2.4 Hz, 10 Hz), 3.36 (s,3H), 3.14 (m, 1H), 2.86 (t, 2H), 1.92 (m, 2H), 1.69 
(m, 2H). 
13
C NMR (100 MHz, CDCl3): δ 180.8, 157.8, 152.3, 137.6, 134.7, 124.9, 117.5, 116.8, 
110.4, 74.8, 59.3, 59.1, 49.4, 36.8, 28.8, 24.1, 16.7. IR (νmax) (KBr): 3422, 2921, 2852, 2361, 
2251, 1742, 1717, 1647, 1612, 1558, 1542, 1508, 1475, 1456, 1418, 1373, 1364, 1340, 1314, 
1268, 1234, 1195, 1175, 1153, 1133, 1063, 1046, 991, 970, 905, 877. HRMS (ESI-TOF):  calc’d 
for C17H19N3O5NaS (M+Na)
+
 400.0943, found: 400.0958.  
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32 
Figure 3-1: 
1
H-NMR spectrum of 32  
26 
 
 
 
32 
Figure 3-2: 
13
C-NMR spectrum of 32  
27 
 
 
 
 
 
 
33 
Figure 3-3: 
1
H-NMR spectrum of 33  
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Figure 3-4: 
13
C-NMR spectrum of 33  
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 Apoptosis is the energy dependent programmed cell death. Improper function of 
apoptosis could lead to diseases such as cancers, strokes, Alziemer’s disease. Caspases are the 
enzymes involved in the later stage of this process. Peptidyl and non-peptidyl caspase inhibitors 
have been synthesized recently. These non-peptidyl compound classes which consist of 
pyrrolidinyl-5-sulfo isatins have showed a greater potency against executioner caspases, caspase-
3 and -7. According to literature and for further caging studies, two compounds were designed, 
synthesized and evaluated their inhibition against caspase-3 in this study. The analog in which its 
N-1 position alkylated with a 4-methyl pyridine moiety (32) showed higher inhibition than the 
analog in which N-1 was alkylated with cyanoethyl group (33). Thus, compound 32 was selected 
for further caging studies with ruthenium. 
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